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brimonidine 0.2% ophthalmic solution. METHODS:
Randomized, controlled trials were conducted in 743
patients to evaluate the original formulation vs. the new
formulation. The new formulation reduced the concen-
tration of the active ingredient from 0.2% to 0.15% and
replaced the preservative, benzalkonium chloride (BAK),
with Purite. Patient outcomes assessed were satisfaction
and comfort level with the product. The economic 
evaluation model estimated the annual cost per patient
including pharmacy and medical ofﬁce visits (including
those that may occur due to adverse events.) RESULTS:
More patients were satisﬁed with the new formulation
(83%) than the original (75%) (p < 0.05). Eighty-ﬁve
percent of patients reported the new formulation was
comfortable vs. 79% for the original. Clinical efﬁcacy (as
measured by IOP reduction) was not different between
the groups. Approximately 90% of the new formulation
patients had no reported ocular allergy (OA) vs. 84% of
the patients using the original formulation (p < 0.05).
Incidence of OA was the primary cost driver in compar-
ing the two formulations, as patients who develop an
ocular allergy require additional resources associated
with OA. The economic model estimated the cost of an
OA patient was $200 more or 36% higher per year than
for an OA free patient, which results in higher overall
treatment costs associated with the original formulation.
CONCLUSIONS: Patients receiving the new reformu-
lated 0.15% brimonidine, rated their treatment satisfac-
tion and comfort level higher than patients on the original
formulation while experiencing the same level of efﬁcacy.
The estimated cost savings for ocular allergy-free patients
would have a positive impact on overall treatment costs.
PES11
QUALITY OF LIFE IN PATIENTS WITH AGE-
RELATED MACULAR DEGENERATION—A
CONJOINT ANALYSIS APPROACH 
Hill AR1,Aspinall PA1, Dhillon B2,Ambrecht AM2, Nelson P2,
Lumsden C2, Brice R3,Vickers A3, Buchholz P4
1Heriot Watt University, Edinburgh, United Kingdom; 2Princess
Alexandra Eye Pavilion, Edinburgh, United Kingdom; 3Adelphi
International Research, Adelphi Mill, Cheshire, United
Kingdom; 4Allergan, Ettlingen, Germany
OBJECTIVES: To study the quality of life (QOL) of
patients with age related macular degeneration (AMD).
METHODS: A group of 81 subjects attending the low
vision and AMD clinic at the Princess Alexandra Eye
Pavilion in Edinburgh were given a battery of tests which
included the VFQ-25. We deﬁned AMD in the following
severity categories: mild, moderate and severe (dry or wet
AMD). In addition to the Quality of Life questionnaires,
patients were given a conjoint analysis task to complete.
The conjoint was to assess aspects of quality of life which
are rarely addressed in conventional questionnaires (i.e.,
patient values and relative importance of different daily
tasks). RESULTS: Background data on the patients
showed a mean age of 77yrs (SD = 6.8); mean binocular
distance logmar of 0.53 (SD = .43); mean binocular near
acuity of 0.7 (SD = 0.44); mean binocular contrast sensi-
tivity (Pelli Robson) of 1.17 (SD = 0.4). Sixty percent of
patients were classed as “severe” AMD, 28% of patients
as “moderate” AMD, and 12% of patients as “mild”
AMD. Results showed that the most signiﬁcant changes
in quality of life as reported through the questionnaires
occurred at the transition between moderate and severe
forms of the disease. The exception was emotionally rel-
evant questions and patient conﬁdence, which showed a
decline between all three AMD states. In addition con-
joint analysis showed that practical tasks associated with
independence had highest priority—that is the order 
of perceived importance from a 5-attribute conjoint task
was outdoor mobility, household chores, reading, recog-
nising faces, and glare. This rank order was preserved in
a shorter 3 attribute conjoint task given to patients with
extremely poor vision. CONCLUSIONS: The most sig-
niﬁcant change in QOL occurred between moderate and
severe forms of the disease. Patient concerns were mainly
over mobility and household tasks, suggesting a priority
for preserving an independent lifestyle.
PES12
AN APPRAISAL OF VISION-RELATED QUALITY
OF LIFE INSTRUMENTS
Mallya U, Nau DP
University of Michigan, Ann Arbor, MI, USA
OBJECTIVES: Visual impairment has been identiﬁed as
one of the most signiﬁcant contributors to lost indepen-
dence, affecting 1.3 million people in the USA. An empha-
sis on improvement of functional limitations among
patients with visual impairment has led to the develop-
ment of vision-related quality of life (QOL) question-
naires in the recent past. The objective of this paper is 
to provide an updated review of published literature on
vision-related QOL instruments and an assessment of
their psychometric properties. METHODS: A review 
of published literature was carried out through the use 
of MEDLINE and QOLID in order to identify vision
related QOL instruments. The instruments were reviewed
in terms of reliability, validity and sensitivity/responsive-
ness, as well as their length and applicability to various
eye disorders. RESULTS: Twenty-four vision-related
QOL instruments were identiﬁed, of which thirteen were
designed for self-administration. Length of the question-
naires varied from 10 to 136 items, and the structure of
scales also varied greatly. Most of the instruments showed
high internal consistency of scales but only few demon-
strated test-retest reliability. Ten of the instruments
focused primarily on visual function, while fourteen also
measured the impact of vision problems on functional
ability. The NEI-VFQ (51 items) and NEI-VFQ-25 are the
only self-administered questionnaires that evaluate eye-
related functional ability and that have shown evidence
of validity, internal consistency and responsiveness across
a broad range of eye disorders including glaucoma,
